Evidence map›Paper›PMID 32095979›Full record

ArticleInflammopharmacology2020

Better outcomes for patients with gout.

Richard Day, Amy Nguyen, Garry Graham, Eindra Aung, Mathew Coleshill, Sophie Stocker

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Regulatory Role of miRNAs and lncRNAs in Gout.Computational and mathematical methods in medicine · 2022
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Richard DaySt Vincent's Clinical School, UNSW Medicine, UNSW Sydney, Sydney, Australia. r.day@unsw.edu.au.ORCID http://orcid.org/0000-0002-6045-6937
Amy NguyenSt Vincent's Clinical School, UNSW Medicine, UNSW Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0003-4603-564X
Garry GrahamDepartment of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, Australia.
Eindra AungSt Vincent's Clinical School, UNSW Medicine, UNSW Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0001-7297-5593
Mathew ColeshillSt Vincent's Clinical School, UNSW Medicine, UNSW Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0003-1906-1893
Sophie StockerSt Vincent's Clinical School, UNSW Medicine, UNSW Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-2114-587X

Funding

National Health and Medical Research Council 1094708
6 · The paper itself

Abstract

Gout is increasing in prevalence despite effective pharmacotherapies. Barriers to effective management are largely educational deficiencies. Sufferers, usually men, need to understand more about gout, especially that maintaining serum urate below 0.36 mmol/L will eliminate recurrent attacks. Also, of great importance is appreciating that sub-optimal adherence to urate-lowering therapy (ULT) will result in a return of attacks. Prescribers also need to understand that acute attacks are likely to occur in the first few months of urate-lowering therapy (ULT), but these can be mitigated by commencing with a dose of ULT reflective of renal function and escalating the dose slowly, every 2-5 weeks until target serum urate is achieved. Prophylaxis against acute attacks over the initial 6 months period of ULT can be enhanced further with concomitant colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs).Gout is largely managed in primary care. Rates of adherence to ULT are 50% or less, worse than most other chronic illnesses. Efforts at educating primary care physicians to, firstly, manage gout effectively and, secondly, to educate their gout patients sufficiently have not been successful. Allied health practitioners, such as nurses, working with prescribers in primary care settings and given the mandate to educate and manage patients with gout, have been spectacularly effective. However, this approach is resource intensive. 'Personalised' eHealth interventions show promise as an alternative strategy, notably in improving adherence to ULT.Numerous applications for smart phones (apps) are now available to assist people with chronic health conditions. Their design needs to accommodate the barriers and enablers perceived by patients to maintaining adherence to prescribed therapies. Personalised feedback of serum urate may represent an important enabler of adherence to ULT in the case of gout.Harnessing mobile apps to support patients managing their chronic illnesses represents an important opportunity to enhance health outcomes. Rigorous, patient-centred and driven development is critical. These tools also require careful evaluation for effectiveness.

Indexed as

Medication AdherenceAnti-Inflammatory Agents, Non-SteroidalColchicineDose-Response Relationship, DrugDrug Therapy, CombinationGoutGout SuppressantsHumansMobile ApplicationsUric AcidAnti-Inflammatory Agents, Non-SteroidalColchicineGout SuppressantsUric AcidAdherenceAllopurinolBarriersDose–responseEnablersGout

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.